Bio-Fd&C바이오에프디엔씨
251120 · KOSDAQ · ₩251120 · 바이오에프디엔씨
₩9,200▼ ₩80 (0.86%)End-of-day · Oct 29, 2026 · End-of-day prices.
Margins
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Gross margin | 66.3% | 67.1% | 69.8% | 70.7% | 69.4% | 59.5% |
| Operating margin | 31.2% | 32.6% | 30.2% | 32.3% | 30.8% | 26.2% |
| Net margin | 32.8% | 34.8% | 28.0% | 35.8% | 27.3% | 24.3% |
Growth (year on year)
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue growth | +1.9% | +19.4% | +3.0% | −1.7% | +32.4% | — |
| Operating income growth | −2.5% | +28.9% | −3.6% | +3.1% | +55.6% | — |
| Net income growth | −3.9% | +48.1% | −19.4% | +28.8% | +49.1% | — |
Returns
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Return on equity | 9.0% | 10.0% | 7.4% | 10.0% | 12.6% | 18.3% |
| Return on assets | 8.6% | 9.5% | 6.9% | 9.2% | 10.6% | 12.6% |
Leverage and liquidity
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Liabilities to equity | 4.7% | 5.2% | 6.6% | 7.2% | 11.4% | 45.1% |
| Net debt to equity | −74.6% | −75.4% | −69.6% | −67.7% | −15.1% | −7.3% |
| Current ratio | 1,908.7% | 1,706.2% | 1,277.6% | 1,117.8% | 750.6% | 135.9% |
Calculated from filed financial statements. TTM = trailing 12 months.
Also known as: Bio-Fd&C / 바이오에프디엔씨 / 251120 / KRX:251120
Source: KRX statistical information